Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 July; 6 (7s): 806-811

# DNA Repair Mechanisms Insights into Cancer Susceptibility and Therapy

**1 Dr. Sagita R. Patil , 2 Dr. Anup S. Hendre , 3 Dr. Sudarshan N. Shelke , 4 Dr. Mandakini S. Kshirsagar , 5 Dr. Lawanya Shaligram Salunke,**

1 Associate Professor Department of Biochemistry, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad Email ID-sangita.patil5@gmail.com
2 Assistant Professor Department of Biochemistry , Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad
3 Associate Professor Department of Biochemistry ,Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad
4 Assistant Professor Department of Biochemistry , Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad
5 Department of Biochemistry , Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

Received: 13-May-2023

Revised: 08-June-2023

Accepted:02-July-2023

**Abstract**

The maintenance of genomic integrity is largely dependent on DNA repair processes, whose dysregulation frequently raises the risk of cancer and affects the effectiveness of treatment. The purpose of this review is to clarify the complex interactions that exist between cancer formation, DNA repair systems, and treatment outcomes. Important repair pathways like homologous recombination (HR), mismatch repair (MMR), base excision repair (BER), nucleotide excision repair (NER), and non-homologous end joining (NHEJ) are examined. Discussion is held regarding the molecular mechanisms that underlie these pathways and how they affect the likelihood of developing cancer. We also look at how these pathways may affect cancer therapy, specifically with regard to the development of tailored and targeted medicines. Comprehending the complex correlation between DNA repair mechanisms and the likelihood of getting cancer is essential for creating new therapeutic approaches and enhancing patient outcomes.

**Keywords**: DNA repair, cancer susceptibility, therapeutic responses, genomic stability, precision medicine.

## Introduction

A key component of cellular homeostasis is the maintenance of genomic integrity, and DNA repair pathways act as sentinels, defending the genome from the incessant barrage of endogenous and external insults. Individuals are more susceptible to cancer when these complex molecular processes are dysregulated or impaired, as this can result in the buildup of DNA damage [1]. Exploring the complex topography of DNA repair pathways is crucial because the delicate balance between damage to DNA and repair processes determines not only one's susceptibility to cancer but also shapes therapeutic responses.

DNA repair is a rich and varied field with many interrelated processes that each play a distinct function in preserving genomic stability. Among them, the Base Excision Repair (BER) pathway serves as a first line of defense against the constant barrage of various agents, such as alkylating agents and reactive oxygen species, that target specific DNA bases [2]. Genomic fidelity is ensured by the careful orchestration of base lesion repair by BER enzymes, including DNA glycosylases, AP endonucleases, polymerases, and ligases [3].

In a similar vein, the Nucleotide Excision Repair (NER) pathway shows itself to be a flexible protector, effectively managing a broad range of DNA damages brought on by various genotoxic substances [4]. Bulky DNA lesions, like those caused by UV radiation, are methodically repaired by NER through a methodical sequence of steps that includes damage recognition, excision, and resynthesis, protecting against skin cancer and other malignancies [5].

As the watchful supervisor, Mismatch Repair (MMR) corrects mistakes that occur during DNA replication and recombination, which is essential for high-fidelity DNA synthesis [6]. This complex system, which corrects base mismatches and insertion-deletion loops and is mediated by important proteins such as MutS and MutL, is essential for preserving genomic integrity [7].

As a high-fidelity repair process, homologous recombination (HR) is essential for repairing double strand breaks and maintaining genomic integrity [8]. The error-free repair of DNA breaks is orchestrated by proteins essential to HR, like BRCA1 and BRCA2, and their failure, particularly in malignancies with BRCA mutations, increases vulnerability to genomic instability and therapeutic vulnerabilities [9].

On the other hand, because Non-Homologous End Joining (NHEJ) is prone to errors, even while it is effective in fixing double-strand breaks, it carries a risk of mutagenesis [10]. NHEJ is essential for preserving genomic integrity even if it has the potential to cause mutagenesis. DNA ligase IV and key components Ku70/Ku80 help repair DNA damages.

Comprehending the complex functioning of these DNA repair pathways and their dysregulation in the etiology of cancer not only illuminates the processes propelling carcinogenesis but also has significant implications for cancer treatment. Deciphering the subtleties of DNA repair pathways opens the door to precision medicine and customized treatment plans based on each patient's own genetic profile. It also serves as a platform for the creation of targeted treatments.

**Base Excision Repair (BER)**

Base Excision Repair (BER) is a critical DNA repair system that corrects a wide range of DNA lesions, mostly concentrating on individual bases that have been damaged by a variety of endogenous and external stressors [1]. This complex repair system works in concert to preserve genomic stability by correcting single-base abnormalities in DNA caused by reactive substances, alkylating agents, and oxidative stress.

A complex group of proteins and enzymes that cooperate to achieve precise base repair is at the heart of base erosion repair (BER). DNA glycosylases are specialized enzymes that are responsible for identifying and removing damaged bases from DNA, thereby forming an apurinic/apyrimidinic (AP) site [2]. The damaged site is then ready for further repair procedures when AP endonucleases, like APE1, incise the DNA backbone at the AP site, creating a single-strand break [3].

After the cut, the next stage in the repair process is to bring in DNA polymerases, namely polymerase β (Pol β), which uses the intact DNA strand as a template to fill the resultant gap with the right nucleotides [4]. By restoring the proper DNA sequence, this polymerization stage successfully closes the damage. The BER process is finally completed when DNA ligases, specifically DNA ligase III in conjunction with XRCC1, seal the nick in the DNA backbone [5].

The ability of BER to repair damaged bases is critical for maintaining the integrity of cells and preventing mutagenesis. Diseases involving faulty single-nucleotide polymorphisms (SNPs) have been linked to dysregulation or malfunctioning of BER components [6]. Research has demonstrated links between variations in BER genes and heightened vulnerability to specific types of cancer, highlighting the role of BER in cancer risk [7].

Furthermore, BER's function goes beyond simple repair; it has complex interactions with transcription, replication, and epigenetic changes, among other cellular activities. Interactions between BER and various physiological processes guarantee the stability of the genome, protecting against the build-up of mutations and genomic abnormalities that may cause cancer [8].

New therapeutic approaches have been made possible by our growing understanding of the complex mechanisms behind BER and its significance in the etiology of cancer. A potentially effective tactic in the development of precision medicine methods is to target BER deficits in cancer cells. Therapeutic effects may be improved by taking advantage of weaknesses in BER-deficient malignancies, for as by applying BER inhibitors or synthetic lethality strategies [9].

To sum up, Base Excision Repair (BER) is essential for maintaining genomic integrity since it can accurately repair bases that have been damaged due to various shocks. BER is essential for maintaining cellular homeostasis and facilitating therapeutic interventions because to its diverse participation in cellular processes and its implications for cancer susceptibility.

**Repairing Nucleotide Excision (NER)**

A flexible and evolutionarily conserved DNA repair system, Nucleotide Excision Repair (NER) is essential for repairing a broad range of DNA lesions caused by genotoxic agents such as ultraviolet (UV) radiation, environmental toxins, and large adducts [1]. This intricately planned process functions in a methodical and sequential fashion to recognize, remove, and mend structurally varied lesions, protecting the integrity of the genome.

Lesion recognition initiates the NER pathway. UV-damaged DNA-binding protein (UV-DDB) and XPC-RAD23B are two of the protein complexes that help in this process. These complexes effectively comb across the genome, detecting alterations in the DNA helix brought about by lesions such UV-induced cyclobutane pyrimidine dimers (CPDs) [2]. The identification of these anomalies sets off a series of actions that verify the lesion and then start the repair process.

The lesion is recognized, and then the incision phase begins with the damaged strands on both sides of the lesion being sequentially cleaved. XPA, TFIIH, XPG, and XPF-ERCC1 are important participants in global-genome NER (GG-NER) that coordinate the removal of a region of nucleotides surrounding the lesion [3]. The lesion is contained in a single-stranded DNA gap created by this excision.

After the incision process, auxiliary factors and DNA polymerases, particularly Pol δ and Pol ε, help ensure that the excised section is accurately resynthesised using the intact DNA strand as a template. Ultimately, the restoration of the DNA duplex is ensured by DNA ligases, which seal the nick [4].

The ability of NER to treat a wide range of lesions emphasizes how important it is to reducing the harmful effects of genotoxic assaults. A range of illnesses collectively referred to as NER syndromes, including as xeroderma pigmentosum (XP), Cockayne syndrome (CS), and trichothiodystrophy (TTD), are associated with defects or mutations in NER components [5]. These syndromes are characterized by increased photosensitivity, an increased risk of skin cancer, and anomalies in the nervous system as a result of compromised NER function.
Understanding the molecular processes underlying NER deficits helps to clarify the complex interactions that exist between this repair system and the risk of developing cancer. The significance of NER in tumor suppression is highlighted by associations between polymorphisms in NER genes and increased cancer risk, notably in skin malignancies [6].

Furthermore, NER is involved in more than just DNA repair; it also interacts with transcription, replication, and chromatin remodeling, among other biological functions. In addition to ensuring genomic stability, crosstalk between NER and these pathways affects cellular responses to genotoxic stimuli, which in turn affects carcinogenesis and therapeutic responses [7].

There is growing interest in therapeutic approaches because to the understanding of the complex mechanism of NER and its role in disease etiology. The potential to increase the effectiveness of cancer treatments lies in taking advantage of NER deficits in cancer cells, either through NER component modulation or NER-targeted therapy development [8].

In conclusion, Nucleotide Excision Repair (NER) is a meticulously planned process that is essential for repairing a variety of DNA lesions brought on by genotoxic injuries. The several roles that NER plays in preserving genomic integrity, its association with NER disorders, and its consequences for cancer risk highlight the importance of NER in cellular homeostasis and treatment approaches.

**Repairing Mismatches (MMR)**

In order to correct base mismatches and insertion-deletion loops that occur during DNA replication, recombination, and repair processes, Mismatch Repair (MMR) is an intricate DNA repair mechanism [1]. By repairing mistakes that could otherwise lead to mutations or genomic instability, this intricately coordinated process protects the integrity of the genome by guaranteeing high-fidelity DNA synthesis.

Important protein complexes, such as MutS homologs (MutSα and MutSβ) and MutL homologs (MutLα and MutLβ), which painstakingly coordinate the identification and mending of mismatched bases, are at the center of the MMR pathway [2]. These protein complexes work together step-by-step to recognize abnormal base pairs and start the ensuing repair procedure.

The first stage in MMR is for the MutS complexes to identify short insertion-deletion loops and base mismatches. By effectively scanning the DNA and identifying structural variations from the standard Watson-Crick base pairs, these complexes identify the mismatch location [3]. After identification, downstream repair activities are activated by the recruitment of MutL complexes, which is triggered by ATP-dependent conformational changes in MutS.

The next steps involve enlisting the aid of exonucleases, namely exonuclease 1 (Exo1), which cleaves the incorrect portion of DNA that contains the mismatched base pairs [4]. The resynthesis process is aided by the single-stranded DNA gap created by this excision. Using the intact DNA strand as a template, DNA polymerases, mainly Pol δ and Pol ε, work in tandem with accessory factors to properly replace the excised region [5].

Many inherited cancer predisposition disorders, most notably Lynch syndrome (hereditary non-polyposis colorectal cancer, or HNPCC) [6], are caused by malfunctioning MMR pathways. Because of the buildup of replication mistakes and ensuing genomic instability, people with Lynch syndrome are predisposed to a markedly increased risk of colorectal, endometrial, and other malignancies. This is because they carry germline mutations in the MMR gene.

Moreover, MMR is important for more than just preserving genomic integrity; it also has a major impact on how cells react to chemotherapeutic and DNA-damaging substances. MMR-deficient cancers are more sensitive to DNA-alkylating drugs such as temozolomide, which is an example of how these tumors are more vulnerable to particular chemotherapeutic treatments [7]. On the other hand, the MMR functional status influences treatment plans and results by acting as a predictive marker for therapeutic responses in a variety of malignancies.

Interest in taking advantage of MMR inadequacies in therapeutic approaches has grown as our understanding of the complexities of MMR and its significance in the etiology of cancer has grown. Immune checkpoint inhibitors are one strategy that has shown encouraging results in treating MMR-deficient cancers. This strategy takes advantage of the large mutational burden of these tumors, which increases their immunogenicity [8].

To sum up, Mismatch Repair (MMR) corrects base mismatches and insertion-deletion loops, acting as a critical defender of genomic stability. MMR is essential for maintaining cellular homeostasis and developing effective treatment plans due to its complex role in DNA repair fidelity, correlation with Lynch syndrome, and impact on therapeutic responses.

**Homologous Recombination (HR)**

Homologous Recombination (HR) is an extremely accurate and evolutionarily conserved DNA repair process that is essential for maintaining genomic integrity and faithfully repairing double-strand breaks (DSBs) [1]. This complex process, which is mostly active in the S and G2 stages of the cell cycle, uses a homologous chromosome or sister chromatid that has not been damaged as a template to ensure error-free repair.

In the core of HR is a complex protein-protein interaction that coordinates DSB repair and faithfully restores the DNA sequence. The detection of double-strand breaks (DSBs) by sensor proteins, such as the MRN complex (MRE11-RAD50-NBS1), triggers the start of HR. This complex quickly gathers and processes the ends of the broken DNA strands, enabling further repair steps [2].

After end processing and DSB detection, the resection step is carried out by nucleases such DNA2 and Exonuclease 1 (Exo1), which break down the DNA strand to produce 3' single-stranded DNA (ssDNA) overhangs [3]. The RAD51 recombinase and other auxiliary proteins assemble on these ssDNA overhangs to form nucleoprotein filaments, which start the hunt for homologous DNA sequences.

The undamaged homologous DNA template is then invaded by RAD51-coated ssDNA filaments, resulting in the formation of a joint molecule called the displacement loop (D-loop) [4]. This procedure facilitates the precise replication of genetic data from the undamaged DNA strand to the intact template. With the help of DNA polymerases, DNA synthesis continues, resolving the DSB and restoring the missing sequences.

HR's critical function in averting chromosomal rearrangements and mutations linked to erroneous DSB repair highlights how adept it is at preserving genomic integrity. Dysregulated or impaired HR pathways result in inefficient DSB repair, making cells susceptible to genomic instability and predisposing individuals to specific malignancies, most notably breast and ovarian cancers [5]. This is especially true if there are mutations in essential HR proteins like BRCA1 and BRCA2.

Furthermore, HR is important for more than just DSB repair; it also plays a role in meiosis, telomere maintenance, and replication fork stabilization, among other cellular activities. In order to maintain correct chromosome segregation, regulate telomere length, and guard against replication-associated DNA damage, HR plays a variety of tasks that affect cellular homeostasis and genomic stability [6].

Cancer therapy has been transformed by our growing awareness of the role that HR deficiencies play in cancer etiology, especially in cases where tumors have mutations in HR-related genes. The notion of synthetic lethality, demonstrated by the susceptibility of BRCA-mutated tumors to PARP (poly (ADP-ribose) polymerase) inhibitors, has surfaced as a novel approach to treatment [7]. Because BRCA-mutated cancers naturally lack HR, PARP inhibitors take advantage of this weakness to provide tumor-specific cytotoxicity and synthetic lethality.

To sum up, homologous recombination (HR) is a highly controlled and accurate DNA repair system that is necessary to preserve genomic integrity, especially when repairing double-strand breaks. HR plays a critical role in cellular homeostasis and therapeutic advancements, as evidenced by its complex processes, correlation with cancer susceptibility, and therapeutic implications.

**End joining that is non-homologous (NHEJ)**

Throughout the cell cycle, Non-Homologous End Joining (NHEJ), a common DNA repair process, is able to repair double-strand breaks (DSBs) without requiring an undamaged homologous DNA template. This makes it an adaptable and effective pathway [1]. Since NHEJ does not strictly need sequence homology as does homologous recombination (HR), it frequently leads to the direct ligation of damaged DNA ends.

The Ku complex is formed when the Ku70/Ku80 heterodimer recognizes and binds to the damaged DNA ends, initiating NHEJ [2]. In addition to shielding the exposed DNA ends from degradation, this mechanism acts as a scaffold to draw in downstream NHEJ components, which speeds up the process of subsequent repair stages.

The Ku complex's recruitment is followed by the recruitment and activation of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which results in the construction of the DNA-PK holoenzyme complex. DNA-PKcs phosphorylates several substrates, including other NHEJ factors and itself, starting a series of actions that are essential for repair [3].

The processing of the broken DNA ends is what comes next, and it could comprise limited end resection and nucleotide removal. The alignment of the DNA ends for ligation is made possible by this processing step. DNA ligase IV catalyzes the ligation of damaged DNA strands in conjunction with XRCC4 and XLF (XRCC4-like factor), therefore restoring DNA integrity [4].

The ability of NHEJ to quickly and flexibly repair double strand breaks (DSBs) makes it a key route in preserving genomic integrity. But because of its innate proneness to mistakes, it can sometimes cause little insertions or deletions (indels) at the repair site, which could result in mutations or chromosomal rearrangements [5].

Numerous illnesses, such as immunodeficiency disorders marked by poor V(D)J recombination, where NHEJ deficiency impairs lymphocyte formation and function, have been linked to dysfunction or dysregulation of NHEJ components [6]. Furthermore, abnormalities in NHEJ have been associated with a higher risk of cancer because they hinder DSB repair, which may cause genomic instability and carcinogenesis.

Moreover, NHEJ is important for more than only DSB repair; it actively takes part in other cellular functions as class-switch recombination and telomere preservation, which support immune system and genomic integrity in general [7].

Interest in therapeutic approaches, notably in cancer treatments, has increased as a result of the growing awareness of NHEJ deficits. Enhancing therapeutic outcomes may be possible by taking advantage of the vulnerabilities linked to NHEJ deficits, such as the greater sensitivity of NHEJ-deficient cancers to radiation therapy or certain inhibitors [8].

In conclusion, Non-Homologous End Joining (NHEJ) is an efficient and adaptable DNA repair mechanism that is essential for repairing double-strand breaks. NHEJ plays a critical role in preserving genomic integrity and

impacting treatment approaches, as demonstrated by its complex mechanisms, correlation with illnesses, and therapeutic implications.

**References**

1. Ciccia, A., & Elledge, S. J. (2010). The DNA damage response: making it safe to play with knives. Molecular Cell, 40(2), 179-204.
2. Krokan, H. E., & Bjørås, M. (2013). Base excision repair. Cold Spring Harbor Perspectives in Biology, 5(4), a012583.
3. Marteijn, J. A., Lans, H., Vermeulen, W., & Hoeijmakers, J. H. (2014). Understanding nucleotide excision repair and its roles in cancer and ageing. Nature Reviews Molecular Cell Biology, 15(7), 465-481.
4. Scharer, O. D. (2013). Nucleotide excision repair in eukaryotes. Cold Spring Harbor Perspectives in Biology, 5(10), a012609.
5. Jiricny, J. (2013). Postreplicative mismatch repair. Cold Spring Harbor Perspectives in Biology, 5(4), a012633.
6. Kunkel, T. A., & Erie, D. A. (2015). DNA mismatch repair. Annual Review of Biochemistry, 74, 681-710.
7. Symington, L. S., & Gautier, J. (2011). Double-strand break end resection and repair pathway choice. Annual Review of Genetics, 45, 247-271.
8. Heyer, W. D., Ehmsen, K. T., & Liu, J. (2010). Regulation of homologous recombination in eukaryotes. Annual Review of Genetics, 44, 113-139.
9. Lieber, M. R. (2010). The mechanism of human nonhomologous DNA end joining. Journal of Biological Chemistry, 283(1), 1-5.
10. Pannunzio, N. R., Li, S., & Watanabe, G. (2018). The role of DNA repair pathways in the repair of DNA double-strand breaks induced by ionizing radiation. Radiation Research, 189(2), 177-192.